TR100 is a specific anti-tropomyosin agent that preferentially disrupts the actin cytoskeleton of tumor cells. TR100 selectively disrupts Tm5NM1/2 containing actin filaments. TR100 induces apoptosis in a panel of neural crest-derived tumor cell lines with no adverse effects on cardiac structure and function.